(R)-Flurbiprofen free base
Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of […
For research use only. Not for human or veterinary use.
(R)-Flurbiprofen structure
CAS No.: 51543-40-9
Pack sizes & pricing
| Size | Price | SKU | Stock | |
|---|---|---|---|---|
| 1 g | USD 360.00 | BP-02409-1g | In stock | Get quote |
| 2 g | USD 580.00 | BP-02409-2g | In stock | Get quote |
| 3 g | USD 695.00 | BP-02409-3g | In stock | Get quote |
| 5 g | USD 927.00 | BP-02409-5g | In stock | Get quote |
| 10 g | USD 1,480.00 | BP-02409-10g | In stock | Get quote |
Need another size or custom synthesis? Request a quote.
Description
Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [ 3H]9-cis-RA to RXRα LBD with IC50 of 75 μM. Tarenflurbil can be used for Alzheimer's disease research.
Biological activity
In Vitro Tarenflurbil ((R)-Flurbiprofen) can significantly reduce Aβ secretion, but at the same time, increases the level of intracellular Aβ. The binding between [3H]9-cis-RA and RXRα is competitively inhibited by both unlabeled (R)-Flurbiprofen and 9-cis-RA. (R)-Flurbiprofen can interfere with the interaction between RXRα and 9-cis-retinoid acid (9-cis-RA), and that 9-cis-RA decreases Tarenflurbil ((R)-Flurbiprofen)’s reduction of Aβ secretion. Tarenflurbil ((R)-Flurbiprofen) treatment significantly increases the levels of intracellular Aβ species[1]. The well characterized, nonsteroidal anti-inflammatory drug (nonsteroidal anti-inflammatory drug), Tarenflurbil ((R)-Flurbiprofen) affects only Aβ and not Notch β formation, indicating that second generation GSMs and nonsteroidal anti-inflammatory drug-based GSMs have different modes of action regarding Notch processing. In Vivo Effects of the early and late onset of treatment with Tarenflurbil ((R)-Flurbiprofen) are assessed in C57BL6/J mice that develop a non-remitting form of the disease, and in SJL mice that develop a relapsing-remitting (RR)-EAE. Tarenflurbil ((R)-Flurbiprofen) completely prevents the development of clinical EAE scores in C57BL6/J mice when the treatment is started within 3 days after immunization. This regimen is referred to as preventive treatment. The effect is dose-dependent, and the minimum daily dose for complete prevention is 5 mg/kg/day. Effects of Tarenflurbil ((R)-Flurbiprofen) are comparable to those of Fingolimod (FTY720, 0.5 mg/kg/day), which is used as the positive control. Tarenflurbil ((R)-Flurbiprofen) also significantly reduces clinical EAE scores in C57BL6/J mice when treatment is started shortly before onset of clinical manifestations, referred to as semi-therapeutic (10 mg/kg/day) and reduces clinical scores when the treatment is initiated after full development of the disease on day 13 (5 mg/g/day).
Identifiers
- SMILES
-
O=C(O)[C@H](C)C1=CC=C(C2=CC=CC=C2)C(F)=C1 - InChIKey
-
SYTBZMRGLBWNTM-SNVBAGLBSA-N
Specifications
- MW (average)
- 244.2609
- Formula
- C15H13FO2
- CAS No.
- 51543-40-9
- Physical state
- Solid
- Color
- White to off-white
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Solubility
Soluble in DMSO : 100 mg/mL